

AD _____

Award Number: DAMD17-98-1-8631

TITLE: Neuroprotective Treatment of Laser-Induced Retinal Injuries

PRINCIPAL INVESTIGATOR: Mordechai Rosner, M.D., M.Med.Sc.
Dr. Yoram Solberg, M. D., Ph.D.
Michael Belkin, M.D., M.A.

CONTRACTING ORGANIZATION: Tel-Aviv University
Tel-Hashomer 52621 Israel

REPORT DATE: October 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20000223 004

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average four per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188) Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1999	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 98 - 1 Sep 99)	
4. TITLE AND SUBTITLE Neuroprotective Treatment of Laser-Induced Retinal Injuries			5. FUNDING NUMBERS DAMD17-98-1-8631	
6. AUTHOR(S) Mordechai Rosner, M.D., M.Med.Sc. Dr. Yoram Solberg, M. D., Ph.D. Michael Belkin, M.D., M.A.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Tel-Aviv University Tel-Hashomer 52621 Israel E-MAIL: mrosner@post.tau.ac.il belkin@mail.netvision.net.il			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) <p><u>Purpose:</u> Laser induced retinal injuries are operational and medical problem in the battlefield as a result of lasers used in military equipment and the introduction of visually incapacitating laser weapons. It is not possible to prevent all these injuries and there is no treatment. This study was designed to evaluate the neuroprotective effect of dextromethorphan, which is FDA approved and clinically used drug, in our rat model of laser-induced retinal-lesions.</p> <p><u>Methods:</u> Argon laser retinal lesions were inflicted in the eyes of 36 pigmented rats. The treated group received dextromethorphan 50 mg/kg dissolved in saline, immediately after exposure to laser and then 20 mg/kg every 8 hours for 3 days. The control group received the solvent at the same volume and schedule. The rats were sacrificed 3, 20 or 60 days later and the retinal lesions were evaluated by light microscopy and morphometric measurements.</p> <p><u>Results:</u> No difference was demonstrated between the treated and the control groups, in the histopathologic appearance of the lesions, their size and the magnitude of photoreceptor nuclei loss within the lesions.</p> <p><u>Conclusions:</u> Dextromethorphan treatment is not effective in ameliorating the retinal injury induced by argon laser in rats, when given systemically at the dose and schedule evaluated.</p>				
14. SUBJECT TERMS Neuroprotection, laser, retina, dextromethorphan, rat			15. NUMBER OF PAGES: 14	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

M. Reaney 31.10.1999
PI - Signature Date

TABLE OF CONTENTS:

	<u>PAGE</u>
FRONT COVER	1
SF 298	2
FOREWORD	3
TABLE OF CONTENTS	4
INTRODUCTION	5
BODY	6
KEY RESEARCH ACCOMPLISHMENTS	9
REPORTABLE OUTCOMES	9
CONCLUSIONS	9
REFERENCES	10
APPENDICES (FIGURES)	12

INTRODUCTION:

Extensive research has focused on protective devices and safety measures to prevent laser-induced retinal injuries, as well as on their treatment. Unfortunately, there is yet no accepted therapy for reducing retinal neuronal death and the associated scarring and disruption of the retinal architecture resulting from exposure to laser radiation. Neuronal lesions tend to spread after an injurious event such as trauma or ischemia, and neuroprotective compounds can minimize this spread and thus limit further damage^{1,2}. We have shown that this is the case in laser-induced retinal lesions as well. Consistent experimental evidence points to the efficacy of non-competitive NMDA antagonists in animal models of CNS global or focal ischemia⁴⁻⁷. Many of these pharmacological compounds are currently undergoing clinical trials for treatment of stroke and traumatic brain injury. One of the most promising is dextromethorphan^{8,9}, a dextrorotatory opioid derivative with both calcium channel and NMDA ion-channel blocking properties¹⁰⁻¹². It was approved for use as an antitussive for many years before its recognition as an NMDA blocker, and it is now in the second phase of clinical trial for traumatic brain injury and neurosurgical prophylaxis. In the current research we evaluated the neuroprotective effectiveness of dextromethorphan, known for its safe usage in healthy human subjects and patients, in our well-established rat model for retinal lesion following argon laser lesions^{3,13-16}. Retinal lesions were induced by argon laser irradiation in retinas of pigmented rats. Thirty-six rats were used for the evaluation of the drug. Eighteen were treated by dextromethorphan and eighteen (the control group) receives the vehicle-saline. The rats were sacrificed at 3, 20 and 60 days after exposure to laser. The efficacy of dextromethorphan treatment in limiting the extent of the injury was evaluated histologically at the acute, intermediate and late phases after injury. The evaluation included light microscopic examination of serial sections, morphometric measurements of the lesion diameter and assessment of the extent of photoreceptor cell loss in the retinal outer nuclear layer.

BODY:

Methods

Animals

Pigmented DA rats (Strain DA/OLa/Hsd, Harlan OLAC Ltd., Blackthorn Bicester Oxon., England; raised in Tel-Aviv University animal house), 90 days old, were used for the experiments. The posterior segment of the eye of this strain has a uniform pigmentation, making it particularly useful for retinal laser injury production. The animals were fed ad libitum with a normal diet and maintained on a 12-h light/dark cycle. They were anesthetized by intraperitoneal injections of ketamine (40 mg/kg) and xylazine (8 mg/kg). Laser retinal lesions were produced in each eye, and the rats were sacrificed after 3, 20 or 60 days by lethal doses of pentobarbital sodium injected intraperitoneally. The eyes were enucleated for histopathologic and morphometric evaluations.

All procedures involving animals were performed according to the guidelines of the Association for Research in Vision and Ophthalmology Resolution on the Use of Animals in Research.

Laser injury

Following dilatation of the pupil with topical topicalamide 0.5% sterile drops (Mydramid, Fischer), a contact lens, specially constructed in our laboratory to fit a rat eye, were coupled to the cornea with 2.5% hydroxypropyl methylcellulose. Six argon laser (Novus 2000, Coherent, Palo Alto Ca) lesions (514 nm, 200 μ m, 0.1 W, 0.05 sec) were produced in each eye, one to three disc diameters from the optic disc. These laser settings were found in our previous studies to result in lesions of uniform size and configuration, involving mainly the outer retinal layers.

Administration of drugs

The treated group received dextromethorphan (d-3-Methoxy-N-methylmorphinon, Sigma Chemical Co., St Louis Missouri) 50 mg/kg dissolved in saline, immediately after exposure to laser and then 20 mg/kg every 8 hours for 3 days. The control group received the solvent at the same volume and schedule.

Experimental design

A total of 36 rats were used in this study. Six laser lesions were produced in each eye of each animal. Half of them (18 rats) served as the test (treated) group, which received intraperitoneal injections of dextromethorphan dissolved in saline and the other half served as the control group and received intraperitoneal injections of the vehicle-saline at the same regimen. The effect of the treatment was evaluated at three time points: 3, 20 and 60 days after the injury was inflicted. The retinal lesions were evaluated for histopathologic and morphometric differences in a masked fashion.

Histopathologic and morphometric studies

The rats were sacrificed 3, 20 or 60 days after irradiation. The eyes were enucleated and fixed in 2% glutaraldehyde. Using a surgical microscope, the posterior segment of the fixed eyes was dissected into tissue samples, each incorporating one retinal laser lesion.

A total of 48 laser lesions from the treated group and 48 laser lesions from the control group (4 laser lesions from each animal) were subjected to both histological and morphometric examination. The tissue samples were embedded in plastic (epon) blocks, sectioned serially (2 μ m) with an ultramicrotome and stained with toluidine-blue.

Stained sections from the central part of the lesion, exhibiting the greatest amount of laser-induced retinal destruction, were examined by light microscopy for histopathological changes of the retinal lesions.

To further evaluate the neuroprotective effects of dextromethorphan, a quantitative morphometric assessment of the retinal lesions were carried out using a computer-assisted image analysis system (Scan Array 2, Galai, Migdal Haemek). Two morphometric measurements were performed on each lesion in order to evaluate the severity of the argon laser injury.

The first measured the largest diameter of the lesion. This was done by determining the edges of the lesion area, according to the changes in the retinal pigmented epithelium and in the cytoarchitecture of the outer retinal layers (Figure 1). These changes included loss of pigment granules in the retinal pigment epithelium, loss of its monolayer structure and loss of retinal pigment epithelial cells, disruption of the outer and inner segments, changes in the outer nuclear layer, and thickness and infolding of the inner retinal layers (the inner nuclear layer, inner plexiform layer, ganglion cell layer and nerve fiber layer). The transition from normal retina to the lesion area is well defined, making the criteria for morphometric measurements clear and reproducible.

The second evaluated the extent (percentage) of photoreceptor cell loss. This was done by calculating the differences between the numbers of ONL nuclei in the outer nuclear layer at the area of the lesion, with that of the normal outer nuclear layer along 100 μm of the retina on both sides of the lesion.

All histopathologic and morphometric evaluations were performed in a masked fashion.

Statistical analysis

A sample size of twelve animals enables to detect any differences between the treated test groups and the vehicle-injected control groups, that is twice the standard deviation within the groups.

All morphometric measurements were performed in two sections at the center of each retinal lesion and averaged. A two-way analysis of variance was used to calculate the significance of the treatment and time effects.

Results

In both treated and control eyes, histopathological examination of the retinal lesions 3 days after laser irradiation revealed damage to the retinal pigment epithelium, the inner and outer segments of the photoreceptors, the outer nuclear layer, the outer plexiform layer and the inner nuclear layer (Figure 1, upper photographs). The retinal pigment epithelium showed local proliferation with formation of a multilayered membrane containing phagocytic cells. The outer and inner segments of the photoreceptors were disrupted and deformed. The outer nuclear layer showed loss of nuclei, as well as the presence of pyknotic nuclei at the periphery, tapering off towards the center of the lesion, where they were completely absent. The center of the lesion was filled with cellular debris, dispersed pigment granules and pigment-laden macrophages. The outer plexiform layer was disrupted and the inner nuclear layer was mildly edematous. The inner plexiform layer, the ganglion cell layer and the nerve fiber layer were folded internally, creating internal bulging at the inner retinal surface over the area of the lesion.

At 20 and 60 days after laser irradiation (Figure 1, middle and lower photographs), the multilayered proliferative membranes in the lesion became more thinned and showed occasional neovascularization. The retinal pigment epithelium layer had reformed. The outer and inner segments of the photoreceptors had reformed at the periphery of the lesion, showing disruption only in the central area. The outer nuclear layer showed fewer pyknotic nuclei, and the central area, in which there was total loss of the outer nuclear layer, had decreased in size. The inner plexiform layer was less edematous. The rest of the histopathological findings did not differ significantly from the findings at 3 days. Bulging of the inner retinal surface was still evident. This bulging was assumed to be a result of the edema of the inner retinal layers at the earlier period, with subsequent traction of the normal retinal layers at the edge of the lesion towards its center once the edema had resolved.

The histological findings of the laser-induced retinal lesions were similar to those described in the literature¹⁷. The histopathological findings in the lesions of the treated group did not differ from those of the control group (Figure 1). Furthermore, there were no significant morphometric differences between the two groups with respect to the diameter of the lesions (Fig. 2) or the loss of photoreceptor nuclei at the injury site (Fig. 3) when examined at 3 days, 20 days or 60 days after laser irradiation.

Discussion

Lasers assume increasing use in communication, industry and the military fields, accounting for increasing numbers of accidental eye injuries¹⁸⁻²⁵. Concern has been growing that lasers might be used as a weapon in the future battlefield, making the eyes a major target²⁶⁻²⁷. Injury to retinal neurons, whether by traumatic, ischemic or other mechanisms, has generally been considered an irreversible phenomenon that cannot be halted or slowed down. There is no accepted therapy available for these devastating injuries. The retina is part of the central nervous system (CNS), and when injured might exhibit similar pathogenic mechanism to those involved in neuronal death following CNS injury²⁸⁻³¹. New insights into these mechanisms have provided a theoretical basis for evaluating various pharmacological strategies to induce neuroprotection. Most of the available information on neuroprotection comes from studies of the CNS following traumatic or ischemic injury. It is now well documented that much of the post-injury tissue damage results from delayed inflammation and an autodestructive cascade of events³¹⁻³². Glutamate receptor antagonists are among the most intensively studied pharmacological agents for reducing neurotoxicity arising out of CNS damage³³⁻³⁶. Glutamate plays a dominant role in CNS¹ as well as retinal neurotransmission^{37,38}. However, exposure of neurons to high concentrations of extracellular glutamate can lead to their death^{1,30}. It is now well established that after CNS injury the damaged neurons release massive amounts of glutamate, which interacts with adjacent cells and eventually destroys them. Thus a biochemical cascade develops, in which injured neurons amplify the initial traumatic effect and cause the damage to spread to neighboring tissue, causing exacerbation of the original insult^{1,30}. The neurocytotoxic action of glutamate appears to be modulated mostly by its N-methyl-D-Aspartate (NMDA) receptor³¹⁻³⁹. Similar neurocytotoxic effects of glutamate, mediated through the activation of NMDA receptors, have been demonstrated in retinal neurons both *in vitro* and *in vivo*⁴⁰⁻⁴², and administration of NMDA-receptor blocker to retinal neurons in culture improved their survival following their exposure to glutamate^{41,43}. Glutamate-receptor blockers also protect retinal neurons from hypoxic damage⁴⁰⁻⁴². It therefore seems likely that the retina might respond to agents shown to have neuroprotective properties in the CNS.

We demonstrated⁶⁷ the neuroprotective effect of MK-801, the "gold-standard" and the most potent known NMDA-receptor antagonist, in argon laser-induced retinal injury. The lesions, which are located in the external retinal layers and the choroid, are reproducible and can be accurately quantified, making it possible to evaluate the potential damage-spread limiting effects of neuroprotective drugs. We followed the histopathological changes in the argon laser-induced retinal lesions for 60 days in MK-801 treated animals (3mg/kg, intraperitoneally) and compared them to those observed in laser lesions inflicted in retinas of control rats injected with saline. We also evaluated the severity of the argon laser injuries in treated and control lesions by morphometric measurement of the diameters of the lesions and the extent of photoreceptor cell losses in the retinal outer nuclear layer. At 20 days and at 60 days, the MK-801-treated lesions were found to be significantly smaller than their control counterparts. Differences in ONL thickness loss between MK-801-treated and control lesions were also highly significant and indicated that significant numbers of ONL neurons were rescued by MK-801 from the spread of the damage. On the basis of these results, we suggest that glutamate plays a key role in the spread of laser-induced retinal injury, by mediating the continuous destruction of the photoreceptors. Antagonism by MK-801 of these glutamate-induced effects significantly improves the outcome. However, the known toxicity of MK-801 precludes its further experimental use in human laser injuries involving the neural retinal elements.

In this study, we examined the effect of dextromethorphan on retinal injury induced by argon laser irradiation in pigmented rats. Dextromethorphan which is a dextrorotatory opioid derivative with both calcium channel and NMDA ion-channel blocking properties¹⁰⁻¹², is now in the second phase of a clinical trial for traumatic brain injury and neurosurgical prophylaxis. The regime used for rats was intraperitoneal injections of dextromethorphan 50 mg/kg dissolved in saline, immediately after exposure to laser and then 20 mg/kg every 8 hours for 3 days. However, the results of the current study show that dextromethorphan treatment, given systemically, at this dose and regimen, was not effective in ameliorating the retinal injury induced by argon laser in rats.

We recommend to continue with the original plan.

KEY RESEARCH ACCOMPLISHMENTS:

- Dextromethorphan treatment, given systemically, at this dose and regimen, was not effective in ameliorating the retinal injury induced by argon laser in rats.

REPORTABLE OUTCOMES:

- manuscripts, abstracts, presentations;	none
- patents and licenses applied for and/or issued;	none
- degrees obtained that are supported by this award;	Basic research by ophthalmologic resident
- development of cell lines, tissue or serum repositories;	none
- informatics such as databases and animal models, etc;	none
- funding applied for based on work supported by this award;	none
- employment or research opportunities applied for and/or received on experiences/training supported by this award.	none

CONCLUSIONS:

Dextromethorphan treatment is not effective in ameliorating the retinal injury induced by argon laser in rats, when given systemically at the dose and schedule evaluated.

We recommend to continue with the original plan to evaluate the effect of the approved drugs mementine and brimonidine.

REFERENCES:

1. Choi DA: The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. *Annu Rev Neurosci.* 1990;13:171-182.
2. Choi DA: Glutamate neurotoxicity and diseases of the nervous system. *Neuron.* 1988;1:623-634.
3. Y. Solberg, M. Rosner, J. Tureyz, M. Belkin MK-801 has neuroprotective and anti-inflammatory effects on retinal laser injury. *Investigative Ophthalmology & Visual Science* Vol. 38, pp. 1380-1389, 1997.
4. Prince DA, Feeser HR: Dextromethorphan protects against cerebral infarction in a rat modal of hypoxia-ischemia. *Neurosci. Lett.* 1988;85:291-296.
5. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J: The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. *Ann Neurol.* 1988;24:543-551.
6. Minematsu K, Fisher M, Li L, Davis MA, Knapp AG, Cotter RE, McBurney RM, Sotak CH: Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assesses by diffusion-weighted MRI. *Neurology.* 1993;43:397-403.
7. Steinberg GK, Kunis D, DeLaPaz R, Poljak A: Neuroprotection following focal cerebral ischemia with the NMDA antagonist dextromethorphan, has a favorable dose response profile. *Neurol. Res.* 1993;15:174-180. Albers GW, Saenz RE, Moses JA, Choi DW: Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia. *Stroke.* 1991;22:1075-1077.
8. Albers GW, Saenz RE, Moses JA, Choi DW: Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia. *Stroke.* 1991;22:1075-1077.
9. Albers GW, Saenz RE, Moses JA: Tolerability of oral dextromethorphan in patients with a history of brain ischemia. *Clin. Neuropharmacol.* 1992;15:509-514.
10. Carpenter CL, Marks SS, Watson DL, Greenberg DA: Dextromethorphan and dextrorphan as calcium channel antagonists. *Brain Res.* 1988;439:372-375.
11. Tortella FC, Klette KL, DeCoster MA, Davis BJ, Newman AH: Dextromethorphan analogs are neuroprotective in vitro and block glutamate-induced excitotoxic calcium signals in neurons. *Neurosci Lett* 1995;198:79-82.
12. Block F, Schwartz M: Dextromethorphan reduces functional deficits and neuronal damage after global ischemia in rats. *Brain Res.* 1996;741:153-159.
13. Rosner M, Tchirkov M, Dubinski G: Animal model of military relevant laser induced eye injuries. The 1994 U.S.A.-Israel Bilateral Medical Research and Development Symposium Abstracts. 1994;16.
14. Rosner M, Tchirkov M, Dubinsky G, et al: Methylprednisolone ameliorates laser induced retinal injury in rtas. ARVO annual meeting, Fort Lauderdale, 1996, p. 694.
15. Solberg Y, Rosner M, Belkin M: Pharmacological treatments of lasere eye injuries by neuroprotection. SPIE, San Jose, 1996, p. 47.
16. M. Rosner, Y. Solberg, J. Tureyz, E. Karin, M. Tchirkov, G. Dubinsky, M. Belkin Neuroprotective therapy for argon-laser induced retinal injury. *Experimental Eye Research*, Vol. 65, pp. 485-495, 1997.
17. Powell JO, Bresnick GH, Yanoff M et al. Ocular effects of argon laser radiation. II. Histopathology of chorioretinal lesions. *Am J Ophthalmol* 1971; 71:1267-1276.
18. Gabel VP, Birngruber R, Lorenz B et al: Clinical observations of six cases of laser injury to the eye. *Health Physics.* 1989;56:705-710.
19. Haifeng L, Guanghuang G, Dechang W, et al: Ocular injuries from accidental laser exposure. *Health Physics.* 1989;56:711-716.
20. Liu H, Gao G, Wu D, et al: Injuries from accidental laser exposure. *Health Physics.* 1989;56:716-718.
21. Kearney JJ, Cohen HB, Stuck B, et al: Laser injury to multiple retinal foci. *Lasers Surg Med.* 1987;7:499-502.
22. Jiemin X, Guiado X, Zhongli C, et al: Experimental studies of the injurrious effects of Q-switched ND:YAG lasers and their outdoor applications. *Health Physics.* 1989;56:647-652.
23. Bdoldrey EE, Little HL, Flocks M, et al: Retinal injury due to industrial laser burns. *Ophthalmology* 1981;88:101-107.

24. Friedmann AI: A natural clinical history of a severe accidental retinal laser burn at the posterior pole of the eye. *Doc Ophthalmol.* 1988;68:395-400.
25. Wolfe JA: Laser retinal injury. *Military Medicine.* 1985;150:177-185.
26. Mellerio J, Marshall J, Tengroth B, et al: Battlefield laser weapons: an assessment of systems, hazards, injuries and ophthalmic resources required for treatment. *Laser Light Ophthalmol.* 1991;4:41-67.
27. Tengroth B, Anderberg B: Blinding laser weapons. *Laser Light Ophthalmol.* 1991;4:35-39.
28. Faden AI: Pharmacotherapy in spinal cord injury: A critical review of recent development. *Clin Neuropharmacol.* 1987;10:193-204.
29. Siesjo BK: Mechanisms of ischemic brain damage. *Crit Care Med.* 1988;16:954-963.
30. Choi DW: The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. *Annu Rev Neurosci.* 1990;13:171-182.
31. Faden AI, Salzman S: Pharmacological strategies in CNS trauma. *Trends in Pharmacol Sci.* 1992;13:29-35.
32. Lipton SA: Molecular mechanisms of trauma-induced neuronal degeneration. *Curr. Opin. Neurol. Neurosurg.* 1993;6:588-596.
33. Peruche B, Kriegelstein J: Mechanisms of drug actions against neuronal damage caused by ischemia: An overview. *Prog. Neuropsychopharmacol. Biol. Psych.* 1993;17:21-70.
34. Scatton B: Excitatory amino acid receptor antagonists: a novel treatment for ischemic cerebrovascular diseases. *Life Sci.* 1994;55:2115-2124.
35. Cottrell JE: Possible mechanisms of pharmacological neuronal protection. *J. Neurosurg. Anaesthesiol.* 1995;7:31-37.
36. Danysz W, Parsons CG, Bresink I, Quack G: Glutamate in CNS disorders. *Drug News and Perspectives.* 1995;8:261-277.
37. Brandon C, Man-Kit Lam D: L-Glutamic acid: A neurotransmitter candidate for cone photoreceptors in human and rat retinas. *Proc Natl Acad Sci USA.* 1983;80:5117-5121.
38. Barstable CJ: Glutamate and GABA in retinal circuitry. *Curr Opin Neurobiol.* 1993;3:520-525.
39. Muir KW, Lees, KR: Clinical experience with excitatory amino acid antagonist drugs. *Stroke.* 1995;26:503-513.
40. Hahn JS, Aizenman E, Lipton SA: Central mammalian neurons normally resistant to glutamate toxicity are made sensitive by elevated extracellular Ca^{2+} : Toxicity is blocked by the N-methyl-D-Aspartate antagonist MK-801. *Proc Natl Acad Sci USA.* 1988;85:6556-6560.
41. el-Asrar AM, Morse PH, Maimone D, Torczynski E, Reder AT: MK-801 protects retinal neurons from hypoxia and the toxicity of glutamate and aspartate. *Invest Ophthalmol Vis Sci.* 1992;33:3463-3468.
42. Siliprandi R, Canella R, Carmignoto G, Schiavo N, Zanellato A, Zannoni R, Vantini G: N-methyl-D-Aspartate-induced neurotoxicity in the adult rat retina. *Vis. Neurosci.* 1992;8:567-573.
43. Levy DI, Lipton SA: Comparison of delayed administration of competitive and uncompetitive antagonists in preventing NMDA receptor-mediated neuronal death. *Neurology.* 1990;40:852-855.
44. Sugawara T, Mori T, Kamei S, Tazawa Y: Protective effect of dextromethorphan on the ischemic retinal damage in rabbit. *Nippon Ganka Gakkai Zasshi.* 1992;96:90-95.
45. Gupta LY, Marmor MF: Mannitol, dextromethorphan and catalase minimize ischemic damage to retinal pigment epithelium and retina. *Arch. Ophthalmol.* 1993;111:384-388.
46. Cao W, Zaharia M, Drumheller A, Casanova C, Lafond G, Brunette JR, Jolicœur FB: Effects of dextromethorphan on ischemia induced electroretinogram changes in rabbit. *Curr. Eye Res.* 1994;13:97-102.
47. Lombardi G, Moroni F, Moroni F: Glutamate receptor antagonists protects against ischemia-induced retinal damage. *Eur. J. Pharmacol.* 1994;271:489-495.

FIGURES




Fig. 1. Retinal lesions of control (left) and dextromethorphan treated (right) at 3 days (upper), 20 days (middle) and 60 days (lower) after laser exposure. (Toluidine blue, Original magnification x100)

Three days after exposure, the control lesion (upper left) showed disruption of the outer nuclear layer with extensive loss of nuclei at the central area of the lesion (asterisk). There was loss of inner and outer segments and development of fusiform proliferative plaque at the level of the retinal pigment epithelium (white arrowhead). An internal retinal bulging was formed at the area of the lesion (white arrowhead). In the dextromethorphan treated rats, 3 days after exposure (upper right) similar findings are seen. Twenty and 60 days after exposure (middle and lower), thinner plaques with occasional neovascularization (white arrow) were seen. The inner and outer segments were reformed. The findings were similar in the dextromethorphan treated and the saline treated control rats.

Fig. 2. Effect of dextromethorphan on the mean retinal lesion diameter.




Fig. 3. Effect of dextromethorphan on the mean percentage of photoreceptor cell loss.

